35.59
price down icon1.66%   -0.60
after-market Handel nachbörslich: 35.59
loading
Schlusskurs vom Vortag:
$36.19
Offen:
$36.06
24-Stunden-Volumen:
1.95M
Relative Volume:
0.74
Marktkapitalisierung:
$9.85B
Einnahmen:
$2.08B
Nettoeinkommen (Verlust:
$466.92M
KGV:
22.81
EPS:
1.56
Netto-Cashflow:
$404.94M
1W Leistung:
-0.42%
1M Leistung:
-3.71%
6M Leistung:
+24.18%
1J Leistung:
+58.04%
1-Tages-Spanne:
Value
$35.34
$36.56
1-Wochen-Bereich:
Value
$35.34
$36.67
52-Wochen-Spanne:
Value
$20.14
$40.02

Exelixis Inc Stock (EXEL) Company Profile

Name
Firmenname
Exelixis Inc
Name
Telefon
(650) 837-7000
Name
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Name
Mitarbeiter
1,147
Name
Twitter
@exelixisinc
Name
Nächster Verdiensttermin
2025-02-11
Name
Neueste SEC-Einreichungen
Name
EXEL's Discussions on Twitter

Vergleichen Sie EXEL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
EXEL
Exelixis Inc
35.59 9.85B 2.08B 466.92M 404.94M 1.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-24 Herabstufung Wells Fargo Overweight → Equal Weight
2025-01-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2025-01-24 Herabstufung Oppenheimer Outperform → Perform
2024-12-20 Herabstufung BMO Capital Markets Outperform → Market Perform
2024-12-17 Herabstufung BofA Securities Buy → Neutral
2024-10-16 Bestätigt RBC Capital Mkts Outperform
2024-09-19 Eingeleitet UBS Neutral
2024-04-11 Herabstufung Barclays Overweight → Equal Weight
2023-12-19 Eingeleitet BTIG Research Buy
2023-12-15 Eingeleitet Citigroup Buy
2023-09-26 Eingeleitet H.C. Wainwright Buy
2023-08-22 Bestätigt Oppenheimer Outperform
2023-08-08 Eingeleitet SVB Securities Market Perform
2023-07-11 Fortgesetzt Morgan Stanley Equal-Weight
2023-05-10 Fortgesetzt Piper Sandler Overweight
2023-03-09 Eingeleitet Wells Fargo Overweight
2023-01-26 Eingeleitet Credit Suisse Outperform
2022-10-18 Eingeleitet JMP Securities Mkt Outperform
2022-06-24 Eingeleitet BMO Capital Markets Outperform
2021-11-19 Eingeleitet Piper Sandler Overweight
2021-11-03 Fortgesetzt Jefferies Buy
2021-10-07 Eingeleitet Jefferies Buy
2021-08-06 Bestätigt H.C. Wainwright Buy
2021-06-15 Eingeleitet H.C. Wainwright Buy
2021-05-18 Fortgesetzt Goldman Sell
2021-03-31 Eingeleitet Credit Suisse Outperform
2021-03-12 Eingeleitet Wolfe Research Outperform
2020-03-04 Eingeleitet Barclays Overweight
2020-01-13 Eingeleitet SunTrust Buy
2019-11-13 Eingeleitet BofA/Merrill Buy
2019-03-18 Hochstufung Morgan Stanley Underweight → Equal-Weight
2018-09-17 Eingeleitet Goldman Neutral
2018-09-10 Eingeleitet Morgan Stanley Underweight
2018-05-11 Bestätigt Needham Buy
2017-10-17 Bestätigt Needham Buy
2017-10-17 Bestätigt RBC Capital Mkts Outperform
2017-10-16 Bestätigt SunTrust Buy
2017-09-22 Herabstufung Leerink Partners Outperform → Mkt Perform
2017-09-15 Eingeleitet RBC Capital Mkts Outperform
2017-09-12 Bestätigt Needham Buy
2017-07-14 Eingeleitet SunTrust Buy
2017-03-31 Eingeleitet Needham Buy
2017-03-16 Eingeleitet Oppenheimer Perform
2017-02-28 Herabstufung Stifel Buy → Hold
2016-11-03 Eingeleitet Deutsche Bank Buy
2016-10-10 Hochstufung Piper Jaffray Neutral → Overweight
2016-09-15 Bestätigt Stifel Buy
Alle ansehen

Exelixis Inc Aktie (EXEL) Neueste Nachrichten

pulisher
Apr 17, 2025

Expert Outlook: Exelixis Through The Eyes Of 19 Analysts - Benzinga

Apr 17, 2025
pulisher
Apr 17, 2025

Citizens JMP reiterates Exelixis stock with $41 target By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 17, 2025

Citizens JMP reiterates Exelixis stock with $41 target - Investing.com

Apr 17, 2025
pulisher
Apr 17, 2025

Exelixis, Inc. (NASDAQ:EXEL) Position Boosted by Summit Investment Advisors Inc. - MarketBeat

Apr 17, 2025
pulisher
Apr 16, 2025

Market Participants Recognise Exelixis, Inc.'s (NASDAQ:EXEL) Earnings - simplywall.st

Apr 16, 2025
pulisher
Apr 16, 2025

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Apr 16, 2025
pulisher
Apr 16, 2025

(EXEL) Investment Analysis - news.stocktradersdaily.com

Apr 16, 2025
pulisher
Apr 11, 2025

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Apr 11, 2025
pulisher
Apr 10, 2025

Prostate Cancer Pipeline Analysis and Clinical Trials - openPR.com

Apr 10, 2025
pulisher
Apr 10, 2025

Private Sector Steps Up in Cancer Research as Federal Support Wavers - Baystreet.ca

Apr 10, 2025
pulisher
Apr 09, 2025

Non-Small-Cell Lung cancer (NSCLC) Pipeline Analysis - openPR.com

Apr 09, 2025
pulisher
Apr 09, 2025

Guggenheim maintains Exelixis stock with $42 target By Investing.com - Investing.com India

Apr 09, 2025
pulisher
Apr 09, 2025

Guggenheim maintains Exelixis stock with $42 target - Investing.com

Apr 09, 2025
pulisher
Apr 08, 2025

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance

Apr 08, 2025
pulisher
Apr 05, 2025

Exelixis (EXEL) Gets a Buy from RBC Capital - The Globe and Mail

Apr 05, 2025
pulisher
Apr 03, 2025

The Smartest Biotech Stocks to Buy With $50 - The Motley Fool

Apr 03, 2025
pulisher
Apr 03, 2025

FY2026 EPS Estimates for Exelixis Lifted by Leerink Partnrs - MarketBeat

Apr 03, 2025
pulisher
Apr 02, 2025

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now? - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Trexquant Investment LP Has $19.82 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Blair William & Co. IL Sells 300,760 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Apr 02, 2025
pulisher
Apr 01, 2025

New Age Alpha Advisors LLC Makes New $2.10 Million Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat

Apr 01, 2025
pulisher
Mar 31, 2025

Exelixis Launches Special Equity Award Program - TipRanks

Mar 31, 2025
pulisher
Mar 30, 2025

(EXEL) Long Term Investment Analysis - news.stocktradersdaily.com

Mar 30, 2025
pulisher
Mar 29, 2025

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors - MSN

Mar 29, 2025
pulisher
Mar 29, 2025

What is Leerink Partnrs' Estimate for Exelixis Q1 Earnings? - MarketBeat

Mar 29, 2025
pulisher
Mar 28, 2025

Exelixis gets FDA nod for its advanced neuroendocrine tumor treatment - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Exelixis stock holds $40 target post FDA nod By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 27, 2025

FDA Expands Exelixis Cabometyx Label For Neuroendocrine Tumors - Barchart.com

Mar 27, 2025
pulisher
Mar 27, 2025

Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL) - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

Exelixis stock holds $40 target post FDA nod - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Stifel maintains Exelixis stock hold, $36 target post FDA nod By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 26, 2025

FDA approves new treatment for advanced neuroendocrine tumors By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis to present positive preclinical data across pipeline portfolio at AACR - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Leerink lifts Exelixis stock target to $33 post FDA approval By Investing.com - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? - Yahoo

Mar 26, 2025
pulisher
Mar 26, 2025

Leerink lifts Exelixis stock target to $33 post FDA approval - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Stifel maintains Exelixis stock hold, $36 target post FDA nod - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis’ primary cancer drug wins FDA approval for neuroendocrine tumors - Endpoints News

Mar 26, 2025
pulisher
Mar 26, 2025

FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Citi maintains Buy on Exelixis stock with $45 target By Investing.com - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

Citi maintains Buy on Exelixis stock with $45 target - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Exelixis' cancer drug gets FDA approval but analysts say its priced in; shares down - TradingView

Mar 26, 2025

Finanzdaten der Exelixis Inc-Aktie (EXEL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):